Periodontal lesions (0.3 × 0.2 cm in size) were treated with a 2.6% collagen matrix alone or a matrix containing adenoviruses encoding luciferase (control), a dominant negative mutant of PDGF-A PDGF-13088), or PDGF-B.
PCR screens of the correct size were treated with exonuclease I and shrimp alkaline phosphatase [ 34] and sequenced at the University of Hawaii's Advanced Studies in Genomics, Proteomics, and Bioinformatics Facility.
All ECC patients (FIGO Stage IB-IIA <4 cm tumor size) were treated with radical hysterectomy plus pelvic lymphadenectomy, while LACC patients (FIGO stage IB-IIA >4 cm tumor size, IIB-IVA) received concomitant chemoradiation (CT/RT) followed by RS in case of response, as previously reported [ 17- 19].
The pristine fumed silica (aerosil A300) with specific surface area of 300 m2/g and 10 12 nm particle size was treated with a toluene solution of phenyltrimethoxysilane (PTMS) (C9H14O3Si).
Large size particles were treated with additional crushing and sieving.
After the tumors had reached ∼100 mm in size, mice were treated with vehicle or 30 mg/kg dabrafenib six days per week.
Tumors of both cell types grew at the same rate, and when they reached a certain size, they were treated with oxaliplatin.
Mice with small, comparably sized tumors were treated with 100 mg/kg Lapatinib (Tyverb, GlaxoSmithKline GmbH & Co. KG, Munich, Germany) by oral gavage (6 days per week with 1 day rest, for 3 weeks) via a gastric cannula by dissolving a 250-mg tablet of Tyverb in HPMC buffer (0.5%hydroxypropyl-methyl-cellulose/0.1hydroxypropyl-methyl-cellulose/0.1hydroxypropyl-methyl-cellulose/0.1%Tween-80Tween-80
Ten days after implant, and once tumours had reached accurately measurable size, mice were treated with 5-FU by itself, 5-FU combined with free d-Ino, or with the [5-FU+d-Ino]-L form as follows: 5-FU: 50 mg kg−1, d-Ino and 120 mg kg−1.
Patients with newly diagnosed breast cancers ≥ 5 cm in size by palpation were treated with docetaxel/cisplatin, both at 70 mg/m2 intravenously every 21 days for 4 courses.
